Bayer

FEATURED ARTICLES ABOUT BAYER - PAGE 4

MUMBAI: UB group chairman Vijay Mallya has been appointed as the chairman of Bayer India. Mallya was appointed chairman at the board meeting held on Thursday, Bayer India informed Stock Exchange here on Friday.

MUMBAI: The open offer by Bayer CropScience AG to shareholders of Aventis Crop Science India Ltd, which was to open ton Wed-nesday, will be delayed as Sebi has sought additional information from the merchant banker about the offer. "The open offer is slightly delayed due to the additional information required by Sebi from Ambit, who are merchant bankers for Bayer CropScience Ag", Bayer said in a statement here.

MUMBAI: UB group chairman Vijay Mallya has been appointed as the chairman of Bayer India. Mallya was appointed chairman at the board meeting held on Thursday, Bayer India informed Stock Exchange here on Friday.

MUMBAI: German drugs & chemicals major Bayer is replacing the head of its Indian operations as part of a global recast. Stephan Gerlich (47) is set to replace Pierrie Louis Dupont as the managing director of Bayer Cropscience, the flagship of Bayer India. Mr Gerlich is expected to assume office shortly. He will continue to head the other group company Bayer Material Sciences. Bayer is understood to have told its employees on Friday of the change at the top. Mr Gerlich addressed a gathering of 60 top executives of Bayer Cropscience at its corporate headquarters in the city on Friday.

MUMBAI: Indian Syntans Investments, the investment arm of the Chennai-based Indian Syntans Group, has raised objections to German conglomerate Bayer's open offer to minority shareholders of Mumbai-based Aventis CropScience. Indian Syntans holds 4.5 per cent in Aventis CropScience India. Though the details could not be ascertained, Indian Syntans Investments appears to disagree with the price of Rs 157 per share being offered by Bayer. Indian Syntans' executives are meeting Sebi officials on Tuesday to take up the matter.

MUMBAI: Cadila Healthcare has signed an agreement with Bayer HealthCare to set up 50:50 joint venture in the name of "Bayer Zydus Pharma" for the sales and marketing of pharmaceutical products in India. The stock was at Rs 807.50, down 1.82 per cent on the BSE. It touched a low of Rs 802 and high of Rs 837 in trade so far.

FRANKFURT: Bayer, the German chemicals group that makes Aspirin, on Wednesday denied allegations to appear in a press report that it had fixed a price for the product with thousands of German pharmacists. "We obviously have recommended prices that are not binding, but in no case do we have price agreements that violate the law," a Bayer spokesman said. According to a report due for release Thursday in the magazine Stern, Bayer is suspected of granting rebates to 11,000 German pharmacists in exchange for their maintaining an elevated price for the widely-used pain reliever.

mumbai: the german multinational bayer ag has finalised the top management structure of the crop science business in india which will be consolidated under a new company called bayer cropscience india. the move is part of bayer ag's global strategy to integrate its agrochemical business with aventis cropscience. bayer ag has informed the bayer india management on february 20, 2002 about the future organisational structure. satish bambani, the head of bayer india's crop protection business, has been designated as the country head for the crop protection business which is proposed to be brought under the ambit of bayer cropscience india, according to sources.

MUMBAI: Indian Syntans Investments, the investment arm of the Chennai-based Indian Syntans Group, has raised objections to German conglomerate Bayer's open offer to minority shareholders of Mumbai-based Aventis CropScience. Indian Syntans holds 4.5 per cent in Aventis CropScience India. Though the details could not be ascertained, Indian Syntans Investments appears to disagree with the price of Rs 157 per share being offered by Bayer. Indian Syntans' executives are meeting Sebi officials on Tuesday to take up the matter.

FRANKFURT: Germany's second-largest listed drugs group Schering AG said on Friday it had no interest in buying Bayer's pharmaceutical business. "Any interest from our side in buying Bayer pharma can be ruled out," Schering Chief Executive Hubertus Erlen told Reuters in an interview. Bayer earlier this month abandoned its insistence that it hold a majority stake in any pharmaceuticals partnership, effectively putting up for sale the undersized business which has a dwindling drug pipeline and is still reeling from last year's recall of cholesterol drug Baycol.